TG4050

P1/2, N=80, Active, not recruiting, Transgene | Trial completion date: Dec 2028 --> Dec 2031

P1, N=64, Completed, Transgene | Active, not recruiting --> Completed | N=23 --> 64 | Trial completion date: Dec 2025 --> Oct 2024

"Transgene..., NEC Corporation...and BostonGene Corporation...announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers. BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services. The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture."

P1, N=23, Active, not recruiting, Transgene | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2024

P1, N=23, Recruiting, Transgene | Trial completion date: Jun 2023 --> Sep 2024 | Trial primary completion date: Jun 2022 --> Sep 2023

P1, N=23, Recruiting, Transgene | N=13 --> 23 | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Jun 2022

In a similar setting, the netMHC 4.0 algorithm yielded a TP of 30% and only identified 39% of positive calls of our algorithm.We demonstrate that the prediction algorithm is accurate in identifying immunogenic cancer mutations even among a large set of candidates. Ongoing TG4050 clinical studies (NCT03839524 and NCT04183166) will allow further validation of the antitumor activity of the elicited immune response.

P1, N=13, Recruiting, Transgene | Not yet recruiting --> Recruiting

P1, N=13, Not yet recruiting, Transgene